Carcinogenesis theory based on estrogen defi ciency;Az ösztrogénhiányon alapuló rákelmé let

Orvosi Hetilap

Volumn 150, Issue 25, 2009, Pages 1155-1166

  Suba, Zsuzsanna ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Breast cancer; Cancer risk; Emlor k; Estrogen deficiency; Hormone replacement therapy; Hormonp tl ter pia; sztrog nhi ny; Oral cancer; R kkock zat; Sz j regi r k

Indexed keywords

ESTROGEN; SEX HORMONE;

CANCER RISK; CARCINOGENESIS; DISEASE ASSOCIATION; ESTROGEN DEFICIENCY; GENE CONTROL; HORMONE SUBSTITUTION; HUMAN; MOUTH CANCER; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; SMOKING;

BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASMS; NEOPLASMS, HORMONE-DEPENDENT; OVARIAN NEOPLASMS; PATIENT SELECTION; POSTMENOPAUSE; PREMENOPAUSE; RECEPTORS, ESTROGEN; RISK FACTORS;

EID: 67650215977     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2009.28646     Document Type: Review

References (92)

1. Suba, Zs.: Gender-related hormonal risk factors for oral cancer. Pathol. Oncol. Res., 2007, 13, 195-202.
2. Kumar, V., Abbas, A. K., Fausto, N. és mtsa: Robbins basic pathology. 8th edition Saunders, Elsevier, 2007.
3. Montag, A., Kumar, V.: The female genital system and breast Chapter 19. In Kumar, V., Abbas, A. K., Fausto, N., Mitchell, R. N. (eds.): Robbins basic pathology. 8th edition. Saunders, Elsevier, 2007.
4. Muti, P., Quattrin, T., Grant, B. J. B. és mtsai: Fasting glucose is a risk factor for breast cancer. Cancer Epidemiol Biomark & Prev., 2002, 11, 1361-1368.
5. Soliman, P. T., Oh, J. C., Schmeler, K, M. és mtsai: Risk factors for young premenopausal women with endometrial cancer. Obstet. Gynecol., 2005, 105, 575-580.
6. Suba, Zs.: Re-evaluation of the epidemiological associations of female sexual steroids and cancer risk. Chapter 6. In Estrogen versus cancer. Nova Science Publishers, Inc., New York, 2009, (in press).
7. Suba, Zs.: Insulin resistance, hyperinsulinemia and cancer risk. Chapter 2. In Estrogen versus cancer. Nova Science Publishers, Inc., New York, 2009, (in press).
8. American Institute For Cancer Research/World Cancer Research Fund: Food, nutrition and the prevention of cancer: a global perspective. American Institute of Cancer Research, Washington, DC, 2002, 252-287.
9. Key, T. J., Applyby, P. N., Reeves, G. K.: Body mass index, serum sex hormones and breast cancer risk in postmenopausal women. J. Natl. Cancer Inst., 2003, 95, 1218-1226.
10. Berrino, F., Muti, P., Micheli, A. és mtsai: Serum sex hormon levels after menopause and subsequent breast cancer. J. Natl. Cancer Inst., 1996, 88, 291-296.
11. Kabuto, M., Akiba, S., Stevens, R. G. és mtsai: A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol. Biomark & Prev., 2000, 9, 575-579.
12. La Vecchia, C., Brinton, L. A., McTiernan, A.: Menopause, hormone replacement therapy and cancer. Maturitas, 2001, 39, 97-115.
13. Brekelmans, C. T.: Risk factors and risk reduction of breast and ovarian cancer. Curr. Opin Obstet. Gynecol., 2003, 15, 63-68.
14. Bloomgarden, Z. T., Second World Congress on the Insulin Resistance Syndrome: Mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy. Diabetes Care, 2005, 28, 1821-1830.
15. Greenle, R. T., Murray, T., Bolden, S. és mtsa: Cancer statistics. CA Cancer J. Clin., 2000, 50, 7-33.
16. Weiderpass, E., Gridley, G., Persson, I. és mtsai: Risk of endometrial and breast cancer in patients with diabetes mellitus. Int. J. Cancer, 1997, 1, 360-363.
17. Horn, L. C., Dietel, M, Einenkel, J.: Hormone replacement therapy (HRT) and endometrial morphology under consideration of the different molecular pathways in endometrial carcinogenesis. Eur. J. Obst. Gyn. Repr. Biol., 2005, 122, 4-12.
18. Anderos, G. L., Judd, H. L., Kaunitz, A. M. és mtsai: Womens's Health Intitative Investigator Effects of estrogen plus progestin on gynaecologic cancers and associated diagnostic producers: The Women's Health Intitative randomised trial. JAMA, 2003, 290, 1739-1748.
19. Ito, K., Utsunomiya, H., Yaegashi, N. és mtsa: Biological roles of estrogen and progesterone in human endometrial carcinoma - new developments in potential endocrine therapy for endometrial cancer. Endocrine Journal, 2007, 54, 667-679.
20. Lax, S. F., Kendall, B., Tashiro, H. és mtsai: Analysis of p53 and K-ras mutations and microsatellite instability suggests distinct molecular genetic pathways in the pathogenesis of uterine endometrioid and serous carcinoma. Cancer, 2000, 88, 814-824.
21. WHO Classifi cation on Pathology and Genetics. In Tavassoli, F. A., Devile, P. (eds.): Tumours of the breast and female genital organs. WHO Publications, Geneva, Switzerland, 2003.
22. Varras, M., Polyzos, D., Akviris, C.: Effects of tamoxifen on the human female genital tract: Review of the literature. Eur. J. Gynaecol. Oncol., 2003, 24, 258-268.
23. Cirisano, F. D., Robboy, S. J., Dodge, R. K. és mtsai: The outcome of state I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrial carcinoma. Gynecol. Oncol., 2000, 77, 55-65.
24. Nand, S. L., Webster, M. A., Baber, R.: The Oestrogen/Provera Study Group. Bleeding pattern and the endometrial changes during continuous combined hormone replacement therapy. Obstet. Gynecol., 1998, 91, 678-684.
25. Sitruk-Warre, R.: Progestogens in hormonal replacement therapy: New molecules, risks and benefi ts. Menopause, 2002, 9, 6-15,
26. Dietel, M., Lewis, M. A., Shapiro, S.: Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Human Reprod., 2005, 20, 2052-2060.
27. Bosetti, C., Negri, E., Franceschi, S. és mtsai: Diet and ovarian cancer risk: a case-control study in Italy. Int. J. Cancer, 2001, 93, 911-915.
28. Risch, H. A.: Hormone replacement therapy and the risk of ovarian cancer. Gynecol. Oncol., 2002, 86, 115-117.
29. Whittemore, A. S., Harris, R., Itnyre, J.: Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IL invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am. J. Epidemiol., 1992, 136, 1184-1203.
30. Negri, E., Tzonou, A., Beral, V. és mtsai: Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int. J. Cancer, 1999, 80, 848-851.
31. Rodriguez, C., Patel, A. V., Calle, E. E. és mtsa: Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. J. Am. Med. Assoc., 2001, 285, 1460-1465.
32. Gambacciani, M., Rosano, G. M., Monteleone, P. és mtsai: Clinical relevance of the HERS trial. Lancet, 2002, 360, 641.
33. Lacey, J. V., Mink, P. J., Lubin, J. H. és mtsai: Menopausal hormone replacement therapy and risk of ovarian cancer. J. Am. Med. Assoc., 2002, 288, 334-341.
34. Schapiro, S.: False alarm: postmenopausal hormone therapy and ovarian cancer. Climacteric., 2007, 10, 466-470.
35. Grady, D.: Postmenopausal hormones - therapy for symptoms only. New Engl. J. Med., 2003, 348, 1-3.
36. Collaborative Group on Hormonal Factors in Breast Cancer: Collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet, 1997, 350, 1047-1059.
37. Anderson, G. L., Limacher, M., Assaf, A. R. és mtsai: Women's Health Intitative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Intitative randomized controlled trial. JAMA, 2004, 291 , 1701-1712.
38. Olsson, H., Bladström, A. M., Ingvar, C.: Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy? Obstet. Gynecol., 2003, 102, 565-570.
39. Adami, H. O., Signorello, L. B., Trichopolos, D.: Towards an understanding of breast cancer etiology. Semin. Cancer Biol., 1998, 8, 255-262.
40. Hofseth, L. J., Raafat, A. M., Osuch, J. R. és mtsai: Hormone replacement therapy with estrogen or estrogen plus medroxy-progesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J. Clin. Endocrinol. Metab., 1999, 84, 4559-4565.
41. Li, C. I., Weiss, N. S., Stanford, J. L. és mtsa: Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer, 2000, 88, 2570-2577.
42. Wisemann, R. A.: Brest cancer hypothesis: a single cause for the majority of cases. J. Epidemiol. Community Haelth, 2000, 54, 851-858.
43. Spratt, J. S., Meyer, J. S., Spratt, J. A.: Rates of growth of human solid neoplasms: part I. J. Surg. Oncol., 1995, 60, 137-146.
44. Shackney, S. E., McCormack, G. W., Cuchural, G. J. Jr.: Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review. Ann. Intern. Med., 1978, 89, 107-121.
45. Spratt, J. S., Spratt, J. A.: What is breast cancer doing before we can detect it? J. Surg. Oncol., 1985, 30, 156-160.
46. Haskell, C. M.: Thorax. Unknown primary-breast cancer in cancer treatment, 2nd ed. WB Saunders Company, 1985.
47. Anderson, T. J., Battersby, S., King, R. J. B. és mtsai: Oral contraceptive use infl uences resting breast proliferation. Hum. Pathol., 1989, 20, 1139-1144.
48. Cutuli, B., Dhermain, F., Magrini, S. M. és mtsai: Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiother. Oncol., 2001, 59, 247-255.
49. Gallus, S., Bosetti, C., Franceschi, S. és mtsai: Oesophageal cancer in women: tobacco, alcohol, nutritional and hormonal factors. Br. J. Cancer, 2001, 85, 341-345.
50. La Vecchia, C., D'Avanzo, B., Franceschi, S. és mtsai: Menstrual and reproductive factors and gastric-cancer risk in women. Int. J. Cancer, 1994, 59, 761-764.
51. Rodriguez, C., Feigelson, H. S., Deka, A. és mtsai: Postmenopausal hormone therapy and lung cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomark & Prev., 2008, 17, 655-660.
52. Castelao, J. E., Yuan, J-M., Skipper, P. L. és mtsai: Gender and smoking-related bladder cancer risk. J. Natl. Cancer Inst., 2001, 93, 538-545.
53. Fernandez, E., La Vecchia, C., Balducci, A. és mtsai: Oral contraceptives and colorectal cancer risk: a meta-analysis. Br. J. Cancer, 2001, 84, 722-727.
54. Parazzini, F., La Vecchia, C., Negri, E. és mtsai: Case-control study of estrogen replacement therapy and risk of cervical cancer. Br. Med. J., 1997, 315, 85-88.
55. Riggs, B. L., Hartmann, L. C.: Selective estrogen-receptor modulators - Mechanisms of action and application to clinical practice. NEJM, 2003, 348, 618-629.
56. Suba, Zs.: Estrogen defi ciency as cancer risk factor. Chapter 5. In Estrogen versus cancer. Nova Science Publishers, Inc., New York, 2009, (in press).
57. Suba, Zs.: Systemic risk factors for oral cancer: Estrogen deficiency and insulin resistance. In Progress in oral cancer research. Ed.: Frederik L. Nielsen. Nova Science Publishers, New York, 2008, 157-172.
58. Coulam, C. B., Annegers, J. F., Kranz, J. S.: Chronic anovulation syndrome and associated neoplasia. Obstet. Gynecol., 1983, 61, 403-407.
59. Hartge, P.: Abortion, breast cancer and epidemiology. N. Engl. J. Med., 1997, 336, 127-128.
60. Pierpoint, T., McKeigue, P. M., Isaacs, A. J. és mtsai: Mortality of women with polycystic ovary syndrome at long-term follow-up. J. Clin. Epidemiol., 1998, 51, 581-586.
61. Gadducci, A., Gargini, A., Palla, E. és mtsai: Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol. Endocrinol., 2005, 20, 200-208.
62. Sartor, B. M., Dickey, R. P.: Polycystic ovarian syndrome and the metabolic syndrome. Am. J. Med., 2005, 330, 336-342.
63. Spritzer, P. M., Morsch, D. M., Wiltgen, D.: Polycystic ovary syndrome associated neoplasms. Arq. Bras. Endocrinol. Metabol., 2006, 49, 805-810.
64. Nestler, J. E., Strauss, J. F.: Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocrin Metab. Clin. North Amer., 1991, 20, 807-823.
65. Polson, D. W., Wadsworth, J., Adams, J. és mtsai: Polycystic ovaries: a common fi nding in normal women. Lancet, 1988, 1, 870-872.
66. Carmina, E., Lobo, R. A.: Polycystic ovaries in hirsute women with normal menses. Am. J. Med., 2001, 111, 602-606.
67. Farquhar, C. M., Birdsall, M., Manning, P. és mtsai: The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aus. NZ Obstet. Gynaecol., 1994, 34, 67-72.
68. Llewellyn, C. D., Johnson, N. W., Warnakulasuriya, K. A. A. S.: Risk factors for squamous cell carcinoma of the oral cavity in young people - a comprehensive literature review. Oral Oncol., 2001, 37, 401-418.
69. Björnström, L., Sjöberg, M.: Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Molecular Endocrinology, 2005, 19, 833-842.
70. Pillay, O. C., Te Fong, L. F., Crow, J. C.: The association between polycystic ovaries and endometrial cancer. Human Reprod., 2006, 21, 924-929.
71. Miller, W. R., O'Neill, J.: The importance of local synthesis of estrogen within the breast. Steroids, 1987, 50, 537-548.
72. Santen, R. J., Martel, J., Hoagland, M. és mtsai: Stromal spindle cells contain aromatase in human breast-tumors. J. Clin. Endo-crin. Metab., 1994, 79, 627-632.
73. MacMahon, B.: Risk factors for endometrial cancer. Gynecol. Oncol., 1974, 2, 122-129.
74. McCullough, L. D., Blizzard, K., Simpson, E. R. és mtsai: Aromatase cytochrome P450 and extragonadal estrogen play a role in ischemic neuroprotection. J. Neurosci., 2003, 23, 8701-8705.
75. Van Landeghem, A. A. J., Poortman, J., Nabuurs, M. és mtsa: Endogenous concentration and subcellular distribution of estrogens in normal and malignant breast tissue. Cancer Res., 1985, 45, 2900-2906.
76. Liehr, J. G.: Is estradiol a genotoxic and mutagenic carcinogen? Endocrine Rev. 2000, 21, 40-54.
77. Faustini-Fustini, M., Rochira, V., Carani, C.: Oestrogen deficiency in men: where are we today? Eur. J. Endocrinol., 1999, 140, 111-129.
78. Carani, C., Qin, K., Simoni, M. és mtsai: Effect of testosterone and estradiol a in man with aromatase defi ciency. N. Engl. J. Med., 1997, 337, 91-95.
79. Smith, E. P., Boyd, J., Frank, G. R. és mtsai: Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N. Engl. J. Med., 1994, 331, 1056-1061.
80. Driggers, P. H., Segars, J. H.: Estrogen action and cytoplasmic signaling pathways. Part II: The role of growth factors and phosphorylation in estrogen signaling. Trends Endocrin Metab., 2002, 13, 422-427.
81. Segars, J., Driggers, P.: Estrogen action and cytoplasmic signaling cascades. Part I: Membrane-associated signaling complexes. Trends Endocrin Metab., 2002, 13, 349-354.
82. Umayahara, Y., Kawamori, R., Watada, H. és mtsai: Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-l enhancer. J. Biol. Chem., 1994, 269, 16433-16442.
83. Kahlert, S., Neudling, S., van Eickels, M. és mtsai: Estrogen receptor α rapidly activates the IGF-1 receptor pathway. J. Biol. Chem., 2000, 275, 18447-18453.
84. Leung, K. C., Johannson, G., Leong, G. M. és mtsa: Estrogen regulation of growth hormone action. Endocrine Rev., 2004, 25, 693-721.
85. Henderson, B. E., Ross, R., Bernstein, L.: Estrogens as a cause of human cancer. Cancer Res., 1988, 48, 246-253.
86. Pietras, R. J., Marquez-Garban, D. C.: Membrane-associated estrogen receptor signaling pathways in human cancers. Clin. Cancer Res., 2007, 13, 4672-4676.
87. Key, T. J., Applyby, P. N., Reeves, G. K. és mtsai: Body mass index, serum sex hormones and breast cancer risk in postmenopausal women. J. Natl. Cancer Inst., 2003, 95, 1218-1226.
88. Marquez, D. C., Pietras, R. J.: Membrane-associated binding sites for estrogen contribute to growth regulation in human breast cancer cells. Oncogene, 2001, 20, 5420-5430.
89. Skov, B. G., Fischer, B. M., Pappot, H.: Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer, 2008, 59, 88-94.
90. Rodriguez, C., Feigelson, H. S., Deka, A. és mtsai: Postmenopau-sal hormone therapy and lung cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomark & Prev., 2008, 17, 655-660.
91. Stoner, M., Wang, F., Wormke, M. és mtsai: Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins. J. Biol. Chem., 2000, 275, 22769-22779.
92. Massarweh, S., Osborne, C. K., Creighton, C. J. és mtsai: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res., 2008, 68, 826-833.